Skip to main content

Vistagen Therapeutics, Inc.

corporate_fare Company Profile

Vistagen Therapeutics, Inc.

VTGN·NASDAQ·Life Sciences·CIK 0001411685

Vistagen Therapeutics, Inc. is a late clinical-stage therapeutics company that develops and aims to commercialize new medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company's neuroscience pipeline includes five clinical-stage intranasal pherine product candidates, each with a novel neurocircuitry-focused proposed mechanism of action and at least one positive clinical study in its targeted patient population. These intranasal pherine product candidates are designed to rapidly, specifically, and selectively bind to peripheral receptors in human nasal chemosensory neurons and activate neurocircuits that are believed to regulate brain areas, without requiring systemic absorption or uptake into the brain for therapeutic benefits. Vistagen Therapeutics, Inc.'s most advanced intranasal pherine product candidate, fasedienol, is currently in a U.S. Phase 3 development program for the acute treatment of social anxiety disorder. Other product candidates include itruvone, which is being developed for the treatment of major depressive disorder; refisolone, for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause; PH15, for the improvement of psychomotor impairment due to mental fatigue; and PH284, for the treatment of cancer cachexia. Social anxiety disorder affects over 30 million adults in the U.S. and typically has an onset early in life, with a reported mean duration of about 20 years.

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for VTGN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Vistagen's Fasedienol Shows Positive Preliminary Safety, Efficacy in Phase 3 Social Anxiety Trial
  • Vistagen Reports Positive Preliminary Data from PALISADE-3 Open-Label Extension for Fasedienol in Social Anxiety
  • Vistagen Completes Phase 3 Trial for Fasedienol in Social Anxiety Disorder; Topline Results Expected Q2 2026
  • FDA Clears Vistagen's Refisolone for U.S. Phase 2 Trials
  • Vistagen Receives FDA Green Light for Refisolone Phase 2 Study in Hot Flashes

Financial Snapshot

Fiscal year ended March 31, 2026
Revenue
$1.27M
Net Income
-$69.69M
Diluted EPS
-$1.83
Op. Cash Flow
-$66.44M
Operating Income
-$72.13M
Cash & Equivalents
$30.79M
Debt / Equity
0.00×
Net Margin
-54.91×
Shares Outstanding
38.07M sh
Source: 10-K · filed 2026-06-15 · accession 0001628280-26-043271
$0.1666 +1.83% today
52-week range · as of 2026-11-13 $0.1638 – $5.14
Market cap
$7.56M
Volume
919.9K (1.1× avg)
3-mo avg 817.4K
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VTGN - Filings & News (Page 2)

VTGN
May 12, 2026, 8:56 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.620
Real-time Price: $0.1666 info
Change: -$0.4534 (-73%) info
Market Cap: $7.556M info
VTGN
May 12, 2026, 7:44 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6361
Real-time Price: $0.1666 info
Change: -$0.4695 (-74%) info
Market Cap: $7.556M info
VTGN
May 08, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6105
Real-time Price: $0.1666 info
Change: -$0.4439 (-73%) info
Market Cap: $7.556M info
VTGN
Apr 28, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.590
Real-time Price: $0.1666 info
Change: -$0.4234 (-72%) info
Market Cap: $7.556M info
VTGN
Apr 28, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5663
Real-time Price: $0.1666 info
Change: -$0.3997 (-71%) info
Market Cap: $7.556M info
VTGN
Apr 02, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5866
Real-time Price: $0.1666 info
Change: -$0.420 (-72%) info
Market Cap: $7.556M info
VTGN
Mar 16, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.626
Real-time Price: $0.1666 info
Change: -$0.4594 (-73%) info
Market Cap: $7.556M info
VTGN
Mar 11, 2026, 7:14 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.5825
Real-time Price: $0.1666 info
Change: -$0.4159 (-71%) info
Market Cap: $7.556M info
VTGN
Feb 20, 2026, 9:12 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.580
Real-time Price: $0.1666 info
Change: -$0.4134 (-71%) info
Market Cap: $7.556M info
VTGN
Feb 12, 2026, 4:38 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.510
Real-time Price: $0.1666 info
Change: -$0.3434 (-67%) info
Market Cap: $7.556M info
VTGN
Feb 12, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.530
Real-time Price: $0.1666 info
Change: -$0.3634 (-69%) info
Market Cap: $7.556M info
VTGN
Feb 06, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5632
Real-time Price: $0.1666 info
Change: -$0.3966 (-70%) info
Market Cap: $7.556M info
VTGN
Jan 09, 2026, 5:26 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.670
Real-time Price: $0.1666 info
Change: -$0.5034 (-75%) info
Market Cap: $7.556M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets